Baird analyst Colleen Kusy raised the firm’s price target on Apellis (APLS) to $50 from $47 and keeps an Outperform rating on the shares. The firm updated its model ahead of Q2 earnings while noting a competitor’s product to Syfovre is nearing C3G approval.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $24 from $23 at BofA
- Apellis Pharmaceuticals: Strong Market Position and Growth Potential Justify Buy Rating
- Apellis Pharmaceuticals: Sustained Growth Potential and Market Resilience Justify Buy Rating
- Apellis price target raised to $26 from $25 at Morgan Stanley
- Cautious Optimism: Apellis Pharmaceuticals’ Strategic Moves and Market Uncertainties Justify Hold Rating